168 related articles for article (PubMed ID: 24121494)
1. Sequential application of a cytotoxic nanoparticle and a PI3K inhibitor enhances antitumor efficacy.
Pandey A; Kulkarni A; Roy B; Goldman A; Sarangi S; Sengupta P; Phipps C; Kopparam J; Oh M; Basu S; Kohandel M; Sengupta S
Cancer Res; 2014 Feb; 74(3):675-685. PubMed ID: 24121494
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
[TBL] [Abstract][Full Text] [Related]
3. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
4. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma.
Guo S; Lopez-Marquez H; Fan KC; Choy E; Cote G; Harmon D; Nielsen GP; Yang C; Zhang C; Mankin H; Hornicek FJ; Borger DR; Duan Z
PLoS One; 2014; 9(4):e93996. PubMed ID: 24695632
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE
Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422
[TBL] [Abstract][Full Text] [Related]
7. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
Qi W; Cooke LS; Stejskal A; Riley C; Croce KD; Saldanha JW; Bearss D; Mahadevan D
BMC Cancer; 2009 May; 9():142. PubMed ID: 19432987
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
[TBL] [Abstract][Full Text] [Related]
9. Bag-1 silencing enhanced chemotherapeutic drug-induced apoptosis in MCF-7 breast cancer cells affecting PI3K/Akt/mTOR and MAPK signaling pathways.
Kilbas PO; Akcay IM; Doganay GD; Arisan ED
Mol Biol Rep; 2019 Feb; 46(1):847-860. PubMed ID: 30661182
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle.
Dreaden EC; Kong YW; Morton SW; Correa S; Choi KY; Shopsowitz KE; Renggli K; Drapkin R; Yaffe MB; Hammond PT
Clin Cancer Res; 2015 Oct; 21(19):4410-9. PubMed ID: 26034127
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
Li W; Sun Q; Song L; Gao C; Liu F; Chen Y; Jiang Y
Eur J Med Chem; 2017 Dec; 141():721-733. PubMed ID: 29107429
[TBL] [Abstract][Full Text] [Related]
12. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
13. Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy.
Kulkarni AA; Roy B; Rao PS; Wyant GA; Mahmoud A; Ramachandran M; Sengupta P; Goldman A; Kotamraju VR; Basu S; Mashelkar RA; Ruoslahti E; Dinulescu DM; Sengupta S
Cancer Res; 2013 Dec; 73(23):6987-97. PubMed ID: 24121488
[TBL] [Abstract][Full Text] [Related]
14. (-)-Liriopein B Suppresses Breast Cancer Progression via Inhibition of Multiple Kinases.
Wang HC; Chang FR; Huang TJ; Kuo CY; Tsai YC; Wu CC
Chem Res Toxicol; 2015 May; 28(5):897-906. PubMed ID: 25856345
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells.
Yi YW; Hong W; Kang HJ; Kim HJ; Zhao W; Wang A; Seong YS; Bae I
J Cell Mol Med; 2013 May; 17(5):648-56. PubMed ID: 23601074
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP
PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846
[TBL] [Abstract][Full Text] [Related]
17. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
[TBL] [Abstract][Full Text] [Related]
18. Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells.
Shi L; Gao X; Li X; Jiang N; Luo F; Gu C; Chen M; Cheng H; Liu P
Curr Mol Med; 2015; 15(5):478-86. PubMed ID: 25941816
[TBL] [Abstract][Full Text] [Related]
19. Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway.
Wang Y; Chen L; Huang G; He D; He J; Xu W; Zou C; Zong F; Li Y; Chen B; Wu S; Zhao W; Wu J
PLoS One; 2013; 8(2):e57391. PubMed ID: 23437382
[TBL] [Abstract][Full Text] [Related]
20. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.
Smith MC; Mader MM; Cook JA; Iversen P; Ajamie R; Perkins E; Bloem L; Yip YY; Barda DA; Waid PP; Zeckner DJ; Young DA; Sanchez-Felix M; Donoho GP; Wacheck V
Mol Cancer Ther; 2016 Oct; 15(10):2344-2356. PubMed ID: 27439478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]